PhRMA slams US state of Mass law

31 August 2008

New legislation in the US state of Massachusetts, which places limits on gifts that drugmakers can give medical professionals, was signed by Governor Deval Patrick, and has been strongly criticised by the Pharmaceutical Research and Manufacturers of America (PhRMA), which just weeks earlier announced its own code of practice with respect to this area of activity (Marketletter July 21).

PhRMA senior vice president Ken Johnson said: "Governor Patrick's decision to sign S2863 is deeply disappointing - and very likely damaging for medical partnerships, clinical research and patients in Massachusetts. The leadership in the state - particularly Governor Patrick - has done much to foster pharmaceutical research and expand patient access to innovative medicines in the state, culminated by the enactment of the Life Sciences Initiative just a few months ago. Unfortunately, Section 14 (Chapter 111N) of S2863 threatens to undermine these promising efforts"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight